Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Wound Infection D014946 12 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cat-Scratch Disease D002372 4 associated lipids
Birth Weight D001724 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Schilling F and Kessler S [Chronic recurrent multifocal osteomyelitis-- I. Review]. 2001 Sep-Oct Klin Padiatr pmid:11582525
Schilling F et al. [Pelvic type of chronic recurrent multifocal osteomyelitis]. 2001 Sep-Oct Klin Padiatr pmid:11582526
Kent JR et al. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. 2001 Jul-Aug Perit Dial Int pmid:11587400
Joloba ML et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. 2001 Clin. Infect. Dis. pmid:11588694
Chahine C et al. Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. 2001 Am J Health Syst Pharm pmid:11596697
Dreses-Werringloer U et al. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. 2001 Antimicrob. Agents Chemother. pmid:11600348
Nagai K et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. 2001 Antimicrob. Agents Chemother. pmid:11600391
Ioannidis JP et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. 2001 J. Antimicrob. Chemother. pmid:11679557
Contopoulos-Ioannidis DG et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. 2001 J. Antimicrob. Chemother. pmid:11679558
Laurent J et al. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 2001 Aliment. Pharmacol. Ther. pmid:11683693
Dubois J and St-Pierre C In vitro susceptibility study of BMS-284756 against Legionella species. 2001 Sep-Oct Diagn. Microbiol. Infect. Dis. pmid:11687318
Kastner U and Guggenbichler JP Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. 2001 Infection pmid:11688901
Golledge CL and Riley TV The efficacy of an antibiotic protocol for community-acquired pneumonia. 2001 Med. J. Aust. pmid:11700844
Toro C et al. [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]. 2001 Rev Esp Quimioter pmid:11704771
Postma MJ et al. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. 2001 May-Jun Value Health pmid:11705188
Pukrittayakamee S et al. Therapeutic responses to antibacterial drugs in vivax malaria. 2001 Sep-Oct Trans. R. Soc. Trop. Med. Hyg. pmid:11706666
Samarendra P et al. QT prolongation associated with azithromycin/amiodarone combination. 2001 Pacing Clin Electrophysiol pmid:11707055
Hand WL and Hand DL Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. 2001 Int. J. Antimicrob. Agents pmid:11711255
Treadway G and Reisman A Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. 2001 Int. J. Antimicrob. Agents pmid:11711256
Page RL et al. Possible interaction between intravenous azithromycin and oral cyclosporine. 2001 Pharmacotherapy pmid:11714218
Weigl LB et al. [Confluent and reticulate papillomatosis. Successful therapy with azithromycin]. 2001 Hautarzt pmid:11715390
Gray RH et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. 2001 Am. J. Obstet. Gynecol. pmid:11717659
Intrauterine devices: antibiotic prophylaxis not necessary during insertion. 2001 Prescrire Int pmid:11718174
Salopek-Rabatić J Chlamydial conjunctivitis in contact lens wearers: successful treatment with single dose azithromycin. 2001 CLAO J pmid:11725983
Butler T Effect of increased inoculum of Salmonella typhi on MIC of azithromycin and resultant growth characteristics. 2001 J. Antimicrob. Chemother. pmid:11733476
Cascio A et al. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. 2002 Clin. Infect. Dis. pmid:11740701
Bain DL et al. Chlamydial genovar distribution after community wide antibiotic treatment. 2001 J. Infect. Dis. pmid:11740734
Aberg JA et al. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. 2001 Nov-Dec HIV Clin Trials pmid:11742432
Najib NM et al. Bioequivalence assessment of Azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)--two brands of azithromycin--in healthy human volunteers. 2001 Biopharm Drug Dispos pmid:11745903
Firsov AA et al. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. 2002 J. Antimicrob. Chemother. pmid:11751774
Chodorowska M et al. [Susceptibility to macrolide antibiotics of Bordetella pertussis and Bordetella parapertussis strains isolated from whooping cough patients in 1968 and in 1997-99]. 2001 Med Dosw Mikrobiol pmid:11757403
Jacks S et al. Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. 2001 Am. J. Vet. Res. pmid:11763173
Bragina EY et al. Electron microscopic evidence of persistent chlamydial infection following treatment. 2001 J Eur Acad Dermatol Venereol pmid:11763379
Swanston WH et al. Single dose (direct observed) azithromycin therapy for Neisseria gonorrhoeae and Chlamydia trachomatis in STD clinic attenders with genital discharge in Trinidad and Tobago. 2001 West Indian Med J pmid:11769023
Phillips P et al. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. 2002 Clin. Infect. Dis. pmid:11774085
Mendes CM et al. In vitro susceptibility of gram-positive cocci isolated from skin and respiratory tract to azithromycin and twelve other antimicrobial agents. 2001 Braz J Infect Dis pmid:11779453
Castor D et al. Antibiotic resistant N. gonorrhoeae in Trinidad and Tobago. 2001 Cell. Mol. Biol. (Noisy-le-grand) pmid:11785665
Oksi J [Diagnostics and treatment of Lyme borreliosis]. 2000 Duodecim pmid:11787113
van der Griend B et al. An uncommon cause of a destructive vulval lesion. 2001 Aust N Z J Obstet Gynaecol pmid:11787928
Kutlin A et al. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. 2002 Antimicrob. Agents Chemother. pmid:11796350
Nagai K et al. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. 2002 Antimicrob. Agents Chemother. pmid:11796375
Skerk V et al. Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. 2001 J Chemother pmid:11806631
Stiefelhagen P [Treatment refractory fever... und then also the kidneys fail]. 2001 MMW Fortschr Med pmid:11808449
Tateda K et al. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. 2000 J. Infect. Chemother. pmid:11810524
Andersen SE et al. [Failed azithromycin treatment of Chlamydia trachomatis infection]. 2001 Ugeskr. Laeg. pmid:11810790
Dawson CR and Schachter J Should trachoma be treated with antibiotics? 2002 Lancet pmid:11812548
Safak MA et al. A comparative study of azithromycin and pseudoephedrine hydrochloride for otitis media with effusion in children. 2001 Acta Otolaryngol. pmid:11813896
Zubata P et al. A new HPLC method for azithromycin quantitation. 2002 J Pharm Biomed Anal pmid:11814725
Lentino JR and Krasnicka B Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. 2002 Int. J. Antimicrob. Agents pmid:11814769
Vorbach H et al. Endothelial cell compatibility of azithromycin and erythromycin. 2002 J. Antimicrob. Chemother. pmid:11815590